We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Masimo (MASI) O3 Regional Oximetry Device Gets FDA Nod
Read MoreHide Full Article
Irvine, CA-based Masimo Corporation (MASI - Free Report) recently announced the receipt of FDA 510(k) clearance for O3 regional oximetry device. The approval will allow the company to market the device in the U.S. for pediatric patients weighing more than 5 kg (11 lbs) and less than 40 kg (88 lbs). The company already had the FDA approval to market the product to adult patients in the US.
Stock Performance
Masimo has had an impressive run on the bourse on a year-to-date basis. The company gained roughly 29.09%, which is higher than the Zacks categorized Medical instruments sub industry’s addition of almost 14.93%.
The current level compares favorably with the S&P 500’s return of 9.74% over the same time frame. This, together with a long-term expected earnings growth rate of 15%, instills confidence in investors.
The estimate revision for the stock has been quite favorable. The year has seen five estimates move north over the last two months, compared with no movement in the opposite direction. As a result, the full-year estimates jumped 6.4% to $2.32 over the same time frame. Masimo currently carries a Zacks Rank #3 (Hold).
Coming back to the news, Masimo’s proprietary O3 regional oximetry uses near-infrared spectroscopy (NIRS) to continuously monitor absolute and trended regional tissue oxygen saturation in the cerebral region. Clinical studies have found that when compared with data obtained from blood samples through induced hypoxia, O3 provided absolute root-mean-squared error of 4% and relative root-mean-squared error of 2.1%.
The addition of O3 to Masimo’s approved devices for non-adult segment in the U.S. will enable clinicians to simultaneously access a number of monitoring technologies including rSO2. The other devices are SedLine Brain Function monitoring, Masimo (Signal Extraction Technology) SET SpO2, PVI and SpHb monitoring.
Bottom Line
These latest developmnets will strengthen the company’s product portfolio, helping Masimo to tap in on the abundant opportunities in the U.S. market. Even the global market trends seem to be quite lucrative, as an analysis by the Global Industry Analysts reveals that the Pulse Oximeters market is projected to reach a worth of $2.3 billion by 2020.
Masimo’s other non-invasive products like SET pulse oximeter and rainbow SET technology have been key growth catalysts. New product launches and growing installed base of its existing devices are going to help Masimo gain greater market traction.
Going forward we believe Masimo’s innovative product portfolio is a key catalyst. Moreover, wider adoption of non-invasive patient monitoring technology will help the company gain market traction. The company’s SET pulse oximetry business represents considerable growth opportunities in international markets.
Stocks to Consider
Better-ranked stocks in the broader medical sector include Luminex Corporation , Edwards Lifesciences Corp. (EW - Free Report) and Accelerate Diagnostics, Inc (AXDX - Free Report) . Notably, Luminex sports a Zacks Rank #1 (Strong Buy), while Edwards Lifesciences and Accelerate Diagnostics carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Luminex has an expected long-term adjusted earnings growth of almost 16.3%. The stock added roughly 7.1% over the last three months.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.6%. The stock has a solid one-year return of around 13.6%.
Accelerate Diagnostics projects long-term adjusted earnings growth of almost 30%. The stock returned 30.9% over the last one year.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Masimo (MASI) O3 Regional Oximetry Device Gets FDA Nod
Irvine, CA-based Masimo Corporation (MASI - Free Report) recently announced the receipt of FDA 510(k) clearance for O3 regional oximetry device. The approval will allow the company to market the device in the U.S. for pediatric patients weighing more than 5 kg (11 lbs) and less than 40 kg (88 lbs). The company already had the FDA approval to market the product to adult patients in the US.
Stock Performance
Masimo has had an impressive run on the bourse on a year-to-date basis. The company gained roughly 29.09%, which is higher than the Zacks categorized Medical instruments sub industry’s addition of almost 14.93%.
The current level compares favorably with the S&P 500’s return of 9.74% over the same time frame. This, together with a long-term expected earnings growth rate of 15%, instills confidence in investors.
The estimate revision for the stock has been quite favorable. The year has seen five estimates move north over the last two months, compared with no movement in the opposite direction. As a result, the full-year estimates jumped 6.4% to $2.32 over the same time frame. Masimo currently carries a Zacks Rank #3 (Hold).
Coming back to the news, Masimo’s proprietary O3 regional oximetry uses near-infrared spectroscopy (NIRS) to continuously monitor absolute and trended regional tissue oxygen saturation in the cerebral region. Clinical studies have found that when compared with data obtained from blood samples through induced hypoxia, O3 provided absolute root-mean-squared error of 4% and relative root-mean-squared error of 2.1%.
The addition of O3 to Masimo’s approved devices for non-adult segment in the U.S. will enable clinicians to simultaneously access a number of monitoring technologies including rSO2. The other devices are SedLine Brain Function monitoring, Masimo (Signal Extraction Technology) SET SpO2, PVI and SpHb monitoring.
Bottom Line
These latest developmnets will strengthen the company’s product portfolio, helping Masimo to tap in on the abundant opportunities in the U.S. market. Even the global market trends seem to be quite lucrative, as an analysis by the Global Industry Analysts reveals that the Pulse Oximeters market is projected to reach a worth of $2.3 billion by 2020.
Masimo’s other non-invasive products like SET pulse oximeter and rainbow SET technology have been key growth catalysts. New product launches and growing installed base of its existing devices are going to help Masimo gain greater market traction.
Going forward we believe Masimo’s innovative product portfolio is a key catalyst. Moreover, wider adoption of non-invasive patient monitoring technology will help the company gain market traction. The company’s SET pulse oximetry business represents considerable growth opportunities in international markets.
Stocks to Consider
Better-ranked stocks in the broader medical sector include Luminex Corporation , Edwards Lifesciences Corp. (EW - Free Report) and Accelerate Diagnostics, Inc (AXDX - Free Report) . Notably, Luminex sports a Zacks Rank #1 (Strong Buy), while Edwards Lifesciences and Accelerate Diagnostics carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Luminex has an expected long-term adjusted earnings growth of almost 16.3%. The stock added roughly 7.1% over the last three months.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.6%. The stock has a solid one-year return of around 13.6%.
Accelerate Diagnostics projects long-term adjusted earnings growth of almost 30%. The stock returned 30.9% over the last one year.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>